Targets › NDMA1
1 program from 1 company in 1 trial: 1 Phase 4; Genitourinary; next expected readout Jun 2029.
Open in Phaseline: the race on NDMA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rutgers, The State University of New Jersey | Isoniazid Enoyl-[acyl-carrier-protein] reductase inhibitor | NDMA1 | Phase 4 | Latent Tuberculosis | Jun 2029 |
Latent Tuberculosis (1)
small molecule (1)
Rutgers, The State University of New Jersey (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.